PDCD1 and neoplasm: The emerging biomarkers for ICI efficacy include, principally, (i) programmed cell death-1 (PD1), (ii) its ligand-1 (PD-L1) and (iii) high levels of tumor-infiltrating lymphocytes (TILs) [16,17,18].